Home Applications 207561 Application 207561
Type NDA
Sponsor GILEAD SCIENCES INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 GENVOYA COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE TABLET;ORAL 150MG;150MG;200MG;EQ 10MG BASE Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N207561-001 GENVOYA COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE 150MG;150MG;200MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2015-11-05
Orange Book patents# Current patent rows page 1 of 1 · 18 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N207561-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2015-12-01 N207561-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2015-12-01 N207561-001 8981103 2026-10-26 Drug substance, Drug product 2015-12-01 N207561-001 7176220*PED 2027-02-27 Pediatric extension N207561-001 7635704*PED 2027-04-26 Pediatric extension N207561-001 8981103*PED 2027-04-26 Pediatric extension N207561-001 8148374 2029-09-03 U-1279 Drug substance, Drug product 2015-12-01 N207561-001 9891239 2029-09-03 U-257 Drug product 2018-02-27 N207561-001 8148374*PED 2030-03-03 Pediatric extension N207561-001 9891239*PED 2030-03-03 Pediatric extension N207561-001 8633219 2030-04-30 U-257 Drug product 2015-12-01 N207561-001 8633219*PED 2030-10-30 Pediatric extension N207561-001 8754065 2032-08-15 U-257 Drug substance, Drug product 2015-12-01 N207561-001 9296769 2032-08-15 U-257 Drug substance, Drug product 2016-04-22 N207561-001 10039718 2032-10-06 Drug product 2018-08-28 N207561-001 8754065*PED 2033-02-15 Pediatric extension N207561-001 9296769*PED 2033-02-15 Pediatric extension N207561-001 10039718*PED 2033-04-06 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 45 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N207561-001 GENVOYA 150MG;150MG;200MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2015-11-05 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N207561-001 GENVOYA 150MG;150MG;200MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2015-11-05 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N207561-001 GENVOYA 150MG;150MG;200MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2015-11-05 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N207561-001 GENVOYA 150MG;150MG;200MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2015-11-05 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N207561-001 GENVOYA 150MG;150MG;200MG;EQ 10MG BASE TABLET / ORAL RLD, RS 2015-11-05 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 22 · 859 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N207561-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2015-12-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2015-12-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 8981103 2026-10-26 Drug substance, Drug product 2015-12-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 7176220*PED 2027-02-27 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 7635704*PED 2027-04-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 8981103*PED 2027-04-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 8148374 2029-09-03 U-1279 Drug substance, Drug product 2015-12-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 9891239 2029-09-03 U-257 Drug product 2018-02-27 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 8148374*PED 2030-03-03 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 9891239*PED 2030-03-03 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 8633219 2030-04-30 U-257 Drug product 2015-12-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 8633219*PED 2030-10-30 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 8754065 2032-08-15 U-257 Drug substance, Drug product 2015-12-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 9296769 2032-08-15 U-257 Drug substance, Drug product 2016-04-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 10039718 2032-10-06 Drug product 2018-08-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 8754065*PED 2033-02-15 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 9296769*PED 2033-02-15 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N207561-001 10039718*PED 2033-04-06 Pediatric extension d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N207561-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2015-12-01 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2015-12-01 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 8981103 2026-10-26 Drug substance, Drug product 2015-12-01 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 7176220*PED 2027-02-27 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 7635704*PED 2027-04-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 8981103*PED 2027-04-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 8148374 2029-09-03 U-1279 Drug substance, Drug product 2015-12-01 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 9891239 2029-09-03 U-257 Drug product 2018-02-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 8148374*PED 2030-03-03 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 9891239*PED 2030-03-03 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 8633219 2030-04-30 U-257 Drug product 2015-12-01 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 8633219*PED 2030-10-30 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 8754065 2032-08-15 U-257 Drug substance, Drug product 2015-12-01 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 9296769 2032-08-15 U-257 Drug substance, Drug product 2016-04-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 10039718 2032-10-06 Drug product 2018-08-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 8754065*PED 2033-02-15 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 9296769*PED 2033-02-15 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N207561-001 10039718*PED 2033-04-06 Pediatric extension c2088c7a36db…2026-09-14 22:38:34 2026-08 N207561-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2015-12-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207561-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2015-12-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207561-001 8981103 2026-10-26 Drug substance, Drug product 2015-12-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207561-001 7176220*PED 2027-02-27 Pediatric extension 84e616aacf4f…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Genvoya ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE Gilead Sciences, Inc. 34784acf-15ed-4715-b504-eb30430518e9 2025-02-03 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 207561 application number: NDA207561 ndc (product): 61958-1901
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 11 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 50090-2279 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide A-S Medication Solutions NDA Current 61958-1901 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide Gilead Sciences, Inc. NDA Current 61958-1901 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide Gilead Sciences, Inc. NDA Current 61958-1901 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide Gilead Sciences, Inc. NDA Current 61958-1901 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide Gilead Sciences, Inc. NDA Current 61958-1901 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide Gilead Sciences, Inc. NDA Current 61958-1901 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide Gilead Sciences, Inc. NDA Current 70518-0568 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide REMEDYREPACK INC. NDA Current 70518-0568 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide REMEDYREPACK INC. NDA Current 70518-0568 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide REMEDYREPACK INC. NDA Current 70518-0568 Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide REMEDYREPACK INC. NDA Current